Clinical trial

Safety of Effivia®, a Bevacizumab Biosimilar

NCT06313268

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Bevacizumab Biosimilar MB02 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Safety of Effivia®, a Bevacizumab Biosimilar

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2022-08-11

PhaseN/A

Conditions

Metastatic Colorectal Cancerunresolved

Metastatic Cervical Cancerunresolved

Non Squamous Non Small Cell Lung Cancerunresolved

Interventions

Bevacizumab Biosimilar MB02DRUG

Sponsors & collaborators

Laboratorios Liomontlead sponsor

Servicios Especializados en Ensayos Clínicos, S.C.collaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06313268 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.